Relay Therapeutics, Inc. (RLAY) stock
RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$16.51+0.04 (+0.24%)
Close on Nov 18, 2026Market cap $3.62BP/E –Yield –
Relay Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Relay Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $10.35M, up 23.9% year over year. For fiscal 2025 it was $15.36M, up 53.4% from the year before. The highest annual figure on record is $82.65M in fiscal 2020.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.36M | +53.4% |
| FY2024 | Dec 31, 2024 | $10.01M | -60.8% |
| FY2023 | Dec 31, 2023 | $25.55M | +1749.8% |
| FY2022 | Dec 31, 2022 | $1.38M | -54.4% |
| FY2021 | Dec 31, 2021 | $3.03M | -96.3% |
| FY2020 | Dec 31, 2020 | $82.65M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $350.00K | -48.3% |
| Q1 FY2026 | Mar 31, 2026 | $3.00M | -60.9% |
| Q4 FY2025 | Dec 31, 2025 | $7.00M | – |
| Q3 FY2025 | Sep 30, 2025 | $0 | – |
| Q2 FY2025 | Jun 30, 2025 | $677.00K | – |
| Q1 FY2025 | Mar 31, 2025 | $7.68M | -23.3% |
| Q4 FY2024 | Dec 31, 2024 | $0 | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $0 | -100.0% |
| Q1 FY2024 | Mar 31, 2024 | $10.01M | +3855.3% |
| Q3 FY2023 | Sep 30, 2023 | $25.20M | +7226.2% |
| Q2 FY2023 | Jun 30, 2023 | $119.00K | -67.4% |
| Q1 FY2023 | Mar 31, 2023 | $226.00K | -46.1% |
| Q4 FY2022 | Dec 31, 2022 | $253.00K | -55.4% |
| Q3 FY2022 | Sep 30, 2022 | $344.00K | -48.3% |
| Q2 FY2022 | Jun 30, 2022 | $365.00K | -56.8% |
| Q1 FY2022 | Mar 31, 2022 | $419.00K | -56.0% |
| Q4 FY2021 | Dec 31, 2021 | $567.00K | – |
| Q3 FY2021 | Sep 30, 2021 | $666.00K | – |
| Q2 FY2021 | Jun 30, 2021 | $844.00K | – |
| Q1 FY2021 | Mar 31, 2021 | $952.00K | – |
See a number that looks wrong?